Fluoxetine restrains allergic inflammation by targeting an FcÉRI-ATP positive feedback loop in mast cells.
Sci Signal
; 16(802): eabc9089, 2023 09 12.
Article
en En
| MEDLINE
| ID: mdl-37699080
ABSTRACT
There is a clinical need for new treatment options addressing allergic disease. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that have anti-inflammatory properties. We tested the effects of the SSRI fluoxetine on IgE-induced function of mast cells, which are critical effectors of allergic inflammation. We showed that fluoxetine treatment of murine or human mast cells reduced IgE-mediated degranulation, cytokine production, and inflammatory lipid secretion, as well as signaling mediated by the mast cell activator ATP. In a mouse model of systemic anaphylaxis, fluoxetine reduced hypothermia and cytokine production. Fluoxetine was also effective in a model of allergic airway inflammation, where it reduced bronchial responsiveness and inflammation. These data show that fluoxetine suppresses mast cell activation by impeding an FcÉRI-ATP positive feedback loop and support the potential repurposing of this SSRI for use in allergic disease.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Fluoxetina
/
Mastocitos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Sci Signal
Asunto de la revista:
CIENCIA
/
FISIOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos